Navigation Links
Skinvisible Appoints New Vice President of Business Development & Marketing
Date:6/11/2008

Strategic Plan for Invisicare Strengthens

LAS VEGAS, June 11 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI), the developers of Invisicare, a patented polymer delivery system that brings unique therapeutic and marketing benefits to topically applied products, announces a new executive appointment. Doreen McMorran will serve as Vice President of Business Development and Marketing, performing an integral role as the Company continues to grow in terms of new licensees, new products, new alliances as well as expansion into areas outside of dermatology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO)

Ms. McMorran will focus on driving business growth through new licensee acquisition for Skinvisible's formulated products and technology. She will contribute to the on-going strategic direction of the Company and will be charged with identifying and growing the Company's business opportunities. The goal is to identify new revenue streams through the penetration of markets complementary and additional to the Company's prime market of dermatology and to enhance the global reach of the Company.

"We have expanded our sales and marketing efforts in order to maintain our strategic business development momentum on a global scale," stated Mr. Terry Howlett, President and CEO of Skinvisible. "With Ms. McMorran's contacts in the dermatology industry and having her drive our strategic sales and marketing efforts, we are confident that she will successfully lead a focused and strategic sales effort that meets our long term growth objectives. We are excited to have Ms. McMorran on board as we continue to position Invisicare as the #1 choice for companies seeking enhanced features for their products and critical product life cycle management."

Ms. McMorran brings to the Company almost 20 years of experience in the medical and pharmaceutical industry, specifically in the areas of strategic planning, sales and marketing. She has spent the last six years selling to international dermatology and skincare focused companies like Procter and Gamble, Johnson & Johnson, Stiefel, Galderma, Novartis and Graceway, to name a few, providing medical education for physicians and consumers about dermatology conditions, products and treatments. Ms. McMorran, who holds a Bachelor of Commerce (Honors) degree, spent six years in the pharmaceutical industry with Astra Pharma. Additionally she has held senior management level positions with a number of healthcare companies, focusing on business development, sales, marketing and operations.

About Invisicare(R)

Skinvisible has patented its technology and trademarked its polymer delivery system Invisicare(R). Invisicare is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. See: http://www.invisicare.com

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. See: http://www.skinvisible.com

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending March 30, 2008)

Corporate Contact:

Terry Howlett, President/CEO

Skinvisible Pharmaceuticals, Inc.

Phone: 702-433-7154

Email: info@skinvisible.com


'/>"/>
SOURCE Skinvisible, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Skinvisible Signs Licensing Agreement for Two Acne Formulations
2. Skinvisible Appoints New Board Member
3. Skinvisible Announces Licensing Agreement for Adapalene
4. Skinvisible Signs Marketing Agreement for India
5. Skinvisible Appoints Dr. George Korkos to Its Advisory Board
6. Skinvisible to Present at Merriman Curhan Ford & Co.s Investor Summit 2007
7. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
8. amfAR Appoints Dr. Annette Sohn as Vice President of Global Initiatives
9. Disc Motion Technologies Appoints Industry Veteran as New CEO
10. Setaram Inc. Appoints New CEO/VP
11. VA Secretary Appoints Panel of National Suicide Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 23, 2017 , ... ... fight against hunger on June 21, 2017, at the Emeryville Center of Community ... and malnutrition around the world. , Rise Against Hunger (formerly Stop Hunger Now) ...
(Date:6/20/2017)... MA (PRWEB) , ... June 20, 2017 , ... ... and CHRISTUS Health, a Texas-based health system, will present how predictive analytics drive ... annual HFMA ANI meeting in Orlando, June 25-28. , “The traditional approach ...
(Date:6/20/2017)... ... 2017 , ... After months of negotiations, FaceCradle USA is proud to announce the debut of ... , “Introducing our product on QVC is something we all worked hard to achieve for ... more than 90 million homes in the United States,” said FaceCradle USA President Dylan Doherty. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, Inc., a leading provider ... titled “ 5 Questions to Ask Before Entering the Maze of Genetic Testing ... Evaluation (GTE) team, the book explores the various types of the more than ...
(Date:6/20/2017)... ... June 20, 2017 , ... Kenneth Mayer, MD, has been appointed ... , Dr. Mayer, who joined the JIAS Editorial Board in 2016, has co-authored more ... Director of Fenway Health and Co-Chair of The Fenway Institute, a member ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: